STOCK TITAN
  1. Home
  2. News
  3. AMRN

Amarin Corp Plc - AMRN STOCK NEWS

Welcome to our dedicated page for Amarin Plc news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin Plc stock.

Amarin Corporation Plc (NASDAQ: AMRN) is a pioneering biopharmaceutical company dedicated to improving cardiovascular health through the development and commercialization of innovative therapeutic products. The company's flagship product, VASCEPA® (icosapent ethyl), is designed to address cardiovascular risks and has received FDA approval in the United States as well as marketing authorization in Europe under the brand name VAZKEPA®.

Amarin's mission is to advance scientific understanding and provide effective treatments for high-risk cardiovascular patients who have not adequately responded to traditional therapies. VASCEPA, a unique form of eicosapentaenoic acid (EPA), has been shown in clinical trials to significantly reduce cardiovascular events, offering a new therapeutic option for patients with elevated triglyceride levels.

In recent years, Amarin has undertaken strategic initiatives to bolster its market presence and financial stability. Notable accomplishments include:

  • Leadership Restructure: In 2023, Amarin appointed new executives, including President & CEO Patrick Holt, to drive the company's global strategy and operational improvements.
  • Revenue Growth in Europe: Amarin reported approximately 65% growth in in-market sales in Europe for Q1 2024 compared to Q4 2023, with significant progress in Spain and the UK.
  • Financial Discipline: The company has implemented measures to reduce operating expenses and preserve cash, closing 2023 with $321 million in cash and no debt.
  • Share Repurchase Plan: In early 2024, Amarin announced a share repurchase plan of up to $50 million to enhance shareholder value, pending necessary approvals.

Amarin's commitment to cardiovascular health extends globally, with operations in the United States, Europe, and partnerships in Canada, China, and other regions. The company continues to explore new market opportunities and strengthen its intellectual property portfolio, as evidenced by the recent extension of VAZKEPA's patent protection in Europe until 2039.

For more information, visit www.amarincorp.com and the dedicated VASCEPA site at www.vascepa.com.

News

 Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023

Rhea-AI Summary
Amarin Corporation to host conference call to discuss Q3 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.9%
Tags
conferences earnings
-
News

Amarin to Present at the 2023 Cantor Global Healthcare Conference

Rhea-AI Summary
Amarin CEO to participate in Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
conferences
-
News

Amarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and Italy

Rhea-AI Summary
Amarin Corporation announced pricing and reimbursement updates for VAZKEPA in the Netherlands and Italy. The Dutch Ministry of Health has approved VAZKEPA for national reimbursement to reduce the risk of cardiovascular events in statin-treated patients with established cardiovascular disease and elevated triglycerides. In Italy, AIFA has issued a decision to not reimburse VAZKEPA at this time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.31%
Tags
none
News

Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel

Rhea-AI Summary
Amarin Corporation and Neopharm Israel have entered into an exclusive marketing and commercialization agreement for VAZKEPA in Israel. VAZKEPA is the first prescription treatment comprised solely of icosapent ethyl, a highly purified form of eicosapentaenoic acid. The agreement follows regulatory approval by Israel's Ministry of Health for VAZKEPA to reduce the risk of cardiovascular events in high-risk patients with elevated triglycerides. Heart disease is the second leading cause of death in Israel for individuals aged 45 and older.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
none
-
News

Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1)

Rhea-AI Summary
Amarin Corporation plc (NASDAQ:AMRN) announces SMC acceptance of VAZKEPA® for reimbursement in Scotland for secondary prevention in high-risk statin-treated patients with established cardiovascular disease. The innovative treatment option aims to reduce the risk of subsequent cardiovascular events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
none
-
News

Amarin Reports Second Quarter 2023 Financial Results

Rhea-AI Summary
Amarin Corporation reported total net revenues of $80 million in the second quarter of 2023, with net product revenues of $65 million and $15 million in license and royalty revenues. The company achieved positive cash flow of $9 million and has a cash position of $313 million. They implemented a cost reduction plan expected to save $40 million over 12 months. The Spanish Drug Pricing Committee recommended national reimbursement of VAZKEPA® in Spain. U.S. product net revenue declined by 22% sequentially to $64.6 million. Amarin is actively filing regulatory submissions for approval in 20 additional countries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
News

Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea

Rhea-AI Summary
Amarin Corporation and Lotus Pharmaceuticals have formed a partnership to distribute and commercialize VAZKEPA across 10 countries, including nine in Southeast Asia and South Korea. VAZKEPA is an innovative treatment option to reduce cardiovascular risk. The partnership will help Amarin expand patient access to VAZKEPA and fuel international growth. The ASEAN region and South Korea have a total hyperlipidemia market of approximately $2 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
partnership
-
News

Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
none
-
News

Amarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA® (icosapent ethyl) in Spain

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
none
News

Amarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick Holt

Rhea-AI Summary
Amarin Corporation announces the compensation program for its new President and CEO, Patrick Holt. The majority of Holt's total target compensation is tied to the creation of shareholder value through stock options. He will be issued a one-time grant of stock options to purchase up to 5,000,000 shares, subject to performance-based vesting with share price hurdles ranging from $2.50 to $15.00. Holt has also agreed to purchase $300,000 worth of Amarin shares in the open market using personal funds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
management

FAQ

What is the current stock price of Amarin Plc (AMRN)?

The current stock price of Amarin Plc (AMRN) is $0.5249 as of November 21, 2024.

What is the market cap of Amarin Plc (AMRN)?

The market cap of Amarin Plc (AMRN) is approximately 215.5M.

What does Amarin Corporation do?

Amarin Corporation is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, primarily through its product VASCEPA® (icosapent ethyl).

What is VASCEPA®?

VASCEPA® (icosapent ethyl) is Amarin's FDA-approved product designed to reduce cardiovascular events in high-risk patients by lowering triglyceride levels.

How did Amarin perform financially in recent quarters?

In Q1 2024, Amarin reported total net revenue of $56.5 million, with significant growth in Europe and a stable cash position of $308.2 million.

What recent strategic initiatives has Amarin undertaken?

Amarin has restructured its leadership, reported strong sales growth in Europe, implemented financial discipline measures, and announced a share repurchase plan.

What are the key markets for Amarin's products?

Amarin's key markets include the United States, Europe, Canada, China, and other regions, with ongoing efforts to expand market access and commercialization globally.

What recent achievements have boosted Amarin's market position?

Recent achievements include extending VAZKEPA's patent protection in Europe until 2039 and securing approximately 65% growth in in-market sales in Europe for Q1 2024.

How does VASCEPA® benefit patients?

VASCEPA® has been shown to significantly reduce cardiovascular events in high-risk patients with elevated triglyceride levels, offering a new treatment option beyond traditional therapies.

Who are the key executives at Amarin?

Key executives include President & CEO Patrick Holt, who brings global leadership and turnaround experience to drive the company's strategic initiatives.

What is the purpose of Amarin's share repurchase plan?

The $50 million share repurchase plan aims to enhance shareholder value by buying back shares, subject to necessary approvals.

How does Amarin support its global operations?

Amarin supports its global operations through offices in the United States, Ireland, Switzerland, and partnerships with commercial entities in various regions.

Stock AMRN logo
Amarin Corp Plc

Nasdaq:AMRN

AMRN Rankings

#3795 Ranked by Market Cap
N/A Ranked by Dividends

AMRN Stock Data

215.54M
404.75M
1.6%
17.05%
4.36%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
DUBLIN 2